case. This article further emphasizes the importance of COVID-19 prevention, for which infection prevention strategies and vaccination remain our greatest defense.Dr. Grome is an infectious diseases physician and Epidemic Intelligence Service Officer for the Centers for Disease Control and Prevention, Atlanta, Georgia. She is currently assigned as a field officer at the Tennessee Department of Health in Nashville, Tennessee. Acknowledgment This work was supported by the National Institutes of Health (grant nos. R43 AI155211 and R01 AI139267 awarded to M.G.S.).ReferencesMorris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March–August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1450–6. DOIExternal LinkPubMedExternal LinkGoogle ScholarExternal LinkTenforde MW, Morris SB. Multisystem inflammatory syndrome in adults: coming into focus. Chest. 2021;159:471–2. DOIExternal LinkPubMedExternal LinkGoogle ScholarExternal LinkGodfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al.; California MIS-C Response Team. COVID-19-associated multisystem inflammatory syndrome in children—United States, March–July 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1074–80. DOIExternal LinkPubMedExternal LinkGoogle ScholarExternal LinkNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in adults (MIS-A) case definition information for healthcare providers 2021 [cited 2021 Jul 1]. https://www.cdc.gov/mis/mis-a/hcp.htmlSalzman MB, Huang CW, O’Brien CM, Castillo RD. Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination. Emerg Infect Dis. 2021;27:1944–8. DOIExternal LinkPubMedExternal LinkGoogle ScholarExternal LinkMcAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020;5:142386. DOIExternal LinkPubMedExternal LinkGoogle ScholarExternal LinkAbstract In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting. Vaccine doses among adolescents and total severe acute respiratory syndrome coronavirus 2 infections, Israel, June 1–August 26, 2021. A) Daily frequency of administration of first and second dose of BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com) among adolescents 12–15 years of age. B) Daily cases of severe acute respiratory syndrome coronavirus 2 infection in persons of all ages. Vaccine doses among adolescents and total severe acute respiratory syndrome coronavirus 2 infections, Israel, June 1–August 26, 2021. A) Daily frequency of administration of first and second dose of BNT162b2... In May 2021, the US Food and Drug Administration and the European Medicines Agency expanded existing authorization for BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.comExternal Link) against severe acute respiratory syndrome coronavirus 2